Title:
APPLICATION OF FLUORO-SUBSTITUTED 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDE
Document Type and Number:
WIPO Patent Application WO/2021/032128
Kind Code:
A1
Abstract:
An application, in preparation of medicine for preventing or treating a disease related to a tyrosine kinase, of a compound as represented by formula I, or a pharmaceutically acceptable salt, an ester, a solvate, a prodrug, an active metabolite, a crystal, a stereoisomer, a tautomer, or a geometric isomer thereof, or a pharmaceutical composition comprising the compound as represented by formula I or the pharmaceutically acceptable salt, ester, solvate, prodrug, active metabolite, crystal, stereoisomer, tautomer, or geometric isomer thereof.
Inventors:
PI SHIQING (CN)
XU YAN (CN)
YANG DAIHONG (CN)
ZHOU ZHIGANG (CN)
XU YAN (CN)
YANG DAIHONG (CN)
ZHOU ZHIGANG (CN)
Application Number:
PCT/CN2020/110061
Publication Date:
February 25, 2021
Filing Date:
August 19, 2020
Export Citation:
Assignee:
HUNAN WARRANT PHARMACEUTICAL CO LTD (CN)
HUNAN NEW MEDICAL TECH DEVELOPMENT CO LTD (CN)
HUNAN WARRANT PHARMACEUTICAL TECH DEVELOPMENT CO LTD (CN)
HUNAN NEW MEDICAL TECH DEVELOPMENT CO LTD (CN)
HUNAN WARRANT PHARMACEUTICAL TECH DEVELOPMENT CO LTD (CN)
International Classes:
A61K31/506; A61P3/04; A61P9/00; A61P19/02; A61P19/10; A61P35/00; A61P35/02; A61P35/04; A61P37/06
Foreign References:
| CN106749223A | 2017-05-31 |
Other References:
X. LI, Y. HE, C. H. RUIZ, M. KOENIG, M. D. CAMERON: "Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways", DRUG METABOLISM AND DISPOSITION, PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 37, no. 6, 1 June 2009 (2009-06-01), US, pages 1242 - 1250, XP055455839, ISSN: 0090-9556, DOI: 10.1124/dmd.108.025932
YANG YAN: "Design, Synthesis and Biological Activity of BRD4 and Small-molecule Targeted Tyrosine Kinase Inhibitor", CHINA MASTER’S THESES FULL-TEXT DATABASE - SHANGHAI UNIVERSITY OF APPLIED SCIENCES, 27 May 2018 (2018-05-27), XP055781710, [retrieved on 20210303]
LIU SHUCHANG, ZHANG JIANCUN, CHEN SAIJUAN: "Progress of BCR-ABL Kinase Inhibitors", CHINESE JOURNAL OF PHARMACEUTICALS, HANGHAI YIYAO GONGYE YANJIUYUAN,SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CN, vol. 41, no. 4, 10 April 2010 (2010-04-10), CN, pages 293 - 297, XP055781705, ISSN: 1001-8255
DENG YUAN, TAO SHAN-DONG; ZHANG XIN; MA JING-JING; HE ZHENG-MEI; CHEN YUE; DENG ZHI-KUI; YU LIANG: "Effects of PCI-32765 and Dasatinib on the Acute Lymphoblastic Leukemic Cells and Their Mechanisms", ZHONGGUO SHIYAN XUEYEXUE ZAZHI - JOURNAL OF EXPERIMENTALHEMATOLOGY, ZHONGGUO SHIYAN, XUEYEXUE ZAZHISHE, BEIJING, CN, vol. 25, no. 1, 20 February 2017 (2017-02-20), CN, pages 72 - 79, XP055781697, ISSN: 1009-2137
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
YANG YAN: "Design, Synthesis and Biological Activity of BRD4 and Small-molecule Targeted Tyrosine Kinase Inhibitor", CHINA MASTER’S THESES FULL-TEXT DATABASE - SHANGHAI UNIVERSITY OF APPLIED SCIENCES, 27 May 2018 (2018-05-27), XP055781710, [retrieved on 20210303]
LIU SHUCHANG, ZHANG JIANCUN, CHEN SAIJUAN: "Progress of BCR-ABL Kinase Inhibitors", CHINESE JOURNAL OF PHARMACEUTICALS, HANGHAI YIYAO GONGYE YANJIUYUAN,SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CN, vol. 41, no. 4, 10 April 2010 (2010-04-10), CN, pages 293 - 297, XP055781705, ISSN: 1001-8255
DENG YUAN, TAO SHAN-DONG; ZHANG XIN; MA JING-JING; HE ZHENG-MEI; CHEN YUE; DENG ZHI-KUI; YU LIANG: "Effects of PCI-32765 and Dasatinib on the Acute Lymphoblastic Leukemic Cells and Their Mechanisms", ZHONGGUO SHIYAN XUEYEXUE ZAZHI - JOURNAL OF EXPERIMENTALHEMATOLOGY, ZHONGGUO SHIYAN, XUEYEXUE ZAZHISHE, BEIJING, CN, vol. 25, no. 1, 20 February 2017 (2017-02-20), CN, pages 72 - 79, XP055781697, ISSN: 1009-2137
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
Attorney, Agent or Firm:
INSIGHT INTELLECTUAL PROPERTY LIMITED (CN)
Download PDF: